Publications by authors named "Cyrus M Sayehli"
We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. We assessed once-daily subcutaneous (SC) pasotuxizumab. All SC patients developed antidrug antibodies; therefore, continuous intravenous (cIV) infusion was assessed.
View Article and Find Full Text PDFBackground: To the authors' knowledge, there are no approved therapies for recurrent, metastatic (R/M) salivary gland carcinoma (SGC), but molecularly targeted therapies warrant ongoing investigation. In the current study, the authors have reported on the efficacy of tipifarnib in patients with aggressive HRAS-mutant, R/M SGC.
Methods: The current prospective, nonrandomized, multicenter, international cohort study involved 8 centers and was conducted from May 2015 to June 2019.
Article Synopsis
- * A long-term follow-up study of 38 patients indicated no significant long-term toxicities, particularly neurocognitive impairments, after blinatumomab treatment.
- * The median overall survival for all patients was 4.6 years, with those receiving the maximum tolerated dose of 60 µg/m per day achieving a median survival of 7.7 years, suggesting this dose is key for long-lasting remission in B-NHL cases.
Background: The clinical activity of fibroblast growth factor receptor (FGFR) inhibitors seems restricted to cancers harbouring rare FGFR genetic aberrations. In preclinical studies, high tumour FGFR mRNA expression predicted response to rogaratinib, an oral pan-FGFR inhibitor. We aimed to assess the safety, maximum tolerated dose, recommended phase 2 dose, pharmacokinetics, and preliminary clinical activity of rogaratinib.
View Article and Find Full Text PDF